Review





Similar Products

86
Charles River Laboratories nog
Nog, supplied by Charles River Laboratories, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nog/pm42259603-136-0-14?v=Charles+River+Laboratories
Average 86 stars, based on 1 article reviews
nog - by Bioz Stars, 2026-07
86/100 stars
  Buy from Supplier

86
Jackson Laboratory female nod cg prkdcscidil2rgtm1sug shijic nog mice
Female Nod Cg Prkdcscidil2rgtm1sug Shijic Nog Mice, supplied by Jackson Laboratory, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nog/pmc13275379-40-0-10?v=Jackson+Laboratory
Average 86 stars, based on 1 article reviews
female nod cg prkdcscidil2rgtm1sug shijic nog mice - by Bioz Stars, 2026-07
86/100 stars
  Buy from Supplier

86
Changsheng Bio Technology Co nog mice
Nog Mice, supplied by Changsheng Bio Technology Co, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nog/pmc13198308-94-0-4?v=Changsheng+Bio+Technology+Co
Average 86 stars, based on 1 article reviews
nog mice - by Bioz Stars, 2026-07
86/100 stars
  Buy from Supplier

86
Charles River Laboratories nog hil 15
a , Timeline of the first animal <t>study</t> <t>using</t> <t>NOG-hIL-15</t> (NOG15) mouse ( s.c. , i.p. and i.v. stand for subcutaneous, intraperitoneal and intravenous, respectively). b , Table showing specific amount of cells used for three dosings (see a ) in the humanized animals. c , Human leukocyte antigen (HLA) haplotype information for PBMC donor 416C (green) and 202C (magenta). Note that 416C is HLA-A2-positive. d - f , Data from the humanized mouse study showing tumor volume ( d ), the percent of human CD45 (hCD45) positive cells over total CD45 + cells (hCD45 + plus mCD45 + ) ( e ), and the amount of human hCD45 + /hCD3 - /hCD56 + NK cells ( f ) (see for flow cytometric gating strategy and percent/events conversion). A dotted line in d indicates that mice were supposed to be euthanized when the tumor volume was larger than 3000 mm 3 . Note that mouse 18019 was not euthanized on day 17 hoping the injected CAR-T cells might reduce tumor volume below 3000 mm 3 after the second dosing. A dotted line in e indicates a 20% hCD45 reconstitution cutoff. g , Flow cytometric analysis for hCD45 + cells in peripheral blood collected from mouse 18025 and 18023 on day 20 and 24. See also .
Nog Hil 15, supplied by Charles River Laboratories, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nog/bio_rxiv__64898__2026__05__10__723228-111-12-13?v=Charles+River+Laboratories
Average 86 stars, based on 1 article reviews
nog hil 15 - by Bioz Stars, 2026-07
86/100 stars
  Buy from Supplier

86
Vital River Laboratories male nog mice
a , Timeline of the first animal <t>study</t> <t>using</t> <t>NOG-hIL-15</t> (NOG15) mouse ( s.c. , i.p. and i.v. stand for subcutaneous, intraperitoneal and intravenous, respectively). b , Table showing specific amount of cells used for three dosings (see a ) in the humanized animals. c , Human leukocyte antigen (HLA) haplotype information for PBMC donor 416C (green) and 202C (magenta). Note that 416C is HLA-A2-positive. d - f , Data from the humanized mouse study showing tumor volume ( d ), the percent of human CD45 (hCD45) positive cells over total CD45 + cells (hCD45 + plus mCD45 + ) ( e ), and the amount of human hCD45 + /hCD3 - /hCD56 + NK cells ( f ) (see for flow cytometric gating strategy and percent/events conversion). A dotted line in d indicates that mice were supposed to be euthanized when the tumor volume was larger than 3000 mm 3 . Note that mouse 18019 was not euthanized on day 17 hoping the injected CAR-T cells might reduce tumor volume below 3000 mm 3 after the second dosing. A dotted line in e indicates a 20% hCD45 reconstitution cutoff. g , Flow cytometric analysis for hCD45 + cells in peripheral blood collected from mouse 18025 and 18023 on day 20 and 24. See also .
Male Nog Mice, supplied by Vital River Laboratories, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nog/pm42129801-378-7-10?v=Vital+River+Laboratories
Average 86 stars, based on 1 article reviews
male nog mice - by Bioz Stars, 2026-07
86/100 stars
  Buy from Supplier

86
Vital River Laboratories immunodeficient male nog mice
a , Timeline of the first animal <t>study</t> <t>using</t> <t>NOG-hIL-15</t> (NOG15) mouse ( s.c. , i.p. and i.v. stand for subcutaneous, intraperitoneal and intravenous, respectively). b , Table showing specific amount of cells used for three dosings (see a ) in the humanized animals. c , Human leukocyte antigen (HLA) haplotype information for PBMC donor 416C (green) and 202C (magenta). Note that 416C is HLA-A2-positive. d - f , Data from the humanized mouse study showing tumor volume ( d ), the percent of human CD45 (hCD45) positive cells over total CD45 + cells (hCD45 + plus mCD45 + ) ( e ), and the amount of human hCD45 + /hCD3 - /hCD56 + NK cells ( f ) (see for flow cytometric gating strategy and percent/events conversion). A dotted line in d indicates that mice were supposed to be euthanized when the tumor volume was larger than 3000 mm 3 . Note that mouse 18019 was not euthanized on day 17 hoping the injected CAR-T cells might reduce tumor volume below 3000 mm 3 after the second dosing. A dotted line in e indicates a 20% hCD45 reconstitution cutoff. g , Flow cytometric analysis for hCD45 + cells in peripheral blood collected from mouse 18025 and 18023 on day 20 and 24. See also .
Immunodeficient Male Nog Mice, supplied by Vital River Laboratories, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nog/pm42128929-352-4-12?v=Vital+River+Laboratories
Average 86 stars, based on 1 article reviews
immunodeficient male nog mice - by Bioz Stars, 2026-07
86/100 stars
  Buy from Supplier

86
Koatech Technology Corporation nod shi scid il2 receptor gamma null nog mice
a , Timeline of the first animal <t>study</t> <t>using</t> <t>NOG-hIL-15</t> (NOG15) mouse ( s.c. , i.p. and i.v. stand for subcutaneous, intraperitoneal and intravenous, respectively). b , Table showing specific amount of cells used for three dosings (see a ) in the humanized animals. c , Human leukocyte antigen (HLA) haplotype information for PBMC donor 416C (green) and 202C (magenta). Note that 416C is HLA-A2-positive. d - f , Data from the humanized mouse study showing tumor volume ( d ), the percent of human CD45 (hCD45) positive cells over total CD45 + cells (hCD45 + plus mCD45 + ) ( e ), and the amount of human hCD45 + /hCD3 - /hCD56 + NK cells ( f ) (see for flow cytometric gating strategy and percent/events conversion). A dotted line in d indicates that mice were supposed to be euthanized when the tumor volume was larger than 3000 mm 3 . Note that mouse 18019 was not euthanized on day 17 hoping the injected CAR-T cells might reduce tumor volume below 3000 mm 3 after the second dosing. A dotted line in e indicates a 20% hCD45 reconstitution cutoff. g , Flow cytometric analysis for hCD45 + cells in peripheral blood collected from mouse 18025 and 18023 on day 20 and 24. See also .
Nod Shi Scid Il2 Receptor Gamma Null Nog Mice, supplied by Koatech Technology Corporation, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nog/pm42128301-77-0-9?v=Koatech+Technology+Corporation
Average 86 stars, based on 1 article reviews
nod shi scid il2 receptor gamma null nog mice - by Bioz Stars, 2026-07
86/100 stars
  Buy from Supplier

86
Servicebio Inc nog
a , Timeline of the first animal <t>study</t> <t>using</t> <t>NOG-hIL-15</t> (NOG15) mouse ( s.c. , i.p. and i.v. stand for subcutaneous, intraperitoneal and intravenous, respectively). b , Table showing specific amount of cells used for three dosings (see a ) in the humanized animals. c , Human leukocyte antigen (HLA) haplotype information for PBMC donor 416C (green) and 202C (magenta). Note that 416C is HLA-A2-positive. d - f , Data from the humanized mouse study showing tumor volume ( d ), the percent of human CD45 (hCD45) positive cells over total CD45 + cells (hCD45 + plus mCD45 + ) ( e ), and the amount of human hCD45 + /hCD3 - /hCD56 + NK cells ( f ) (see for flow cytometric gating strategy and percent/events conversion). A dotted line in d indicates that mice were supposed to be euthanized when the tumor volume was larger than 3000 mm 3 . Note that mouse 18019 was not euthanized on day 17 hoping the injected CAR-T cells might reduce tumor volume below 3000 mm 3 after the second dosing. A dotted line in e indicates a 20% hCD45 reconstitution cutoff. g , Flow cytometric analysis for hCD45 + cells in peripheral blood collected from mouse 18025 and 18023 on day 20 and 24. See also .
Nog, supplied by Servicebio Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nog/pm42092462-94-0-8?v=Servicebio+Inc
Average 86 stars, based on 1 article reviews
nog - by Bioz Stars, 2026-07
86/100 stars
  Buy from Supplier

86
Charles River Laboratories spf nog mice
a , Timeline of the first animal <t>study</t> <t>using</t> <t>NOG-hIL-15</t> (NOG15) mouse ( s.c. , i.p. and i.v. stand for subcutaneous, intraperitoneal and intravenous, respectively). b , Table showing specific amount of cells used for three dosings (see a ) in the humanized animals. c , Human leukocyte antigen (HLA) haplotype information for PBMC donor 416C (green) and 202C (magenta). Note that 416C is HLA-A2-positive. d - f , Data from the humanized mouse study showing tumor volume ( d ), the percent of human CD45 (hCD45) positive cells over total CD45 + cells (hCD45 + plus mCD45 + ) ( e ), and the amount of human hCD45 + /hCD3 - /hCD56 + NK cells ( f ) (see for flow cytometric gating strategy and percent/events conversion). A dotted line in d indicates that mice were supposed to be euthanized when the tumor volume was larger than 3000 mm 3 . Note that mouse 18019 was not euthanized on day 17 hoping the injected CAR-T cells might reduce tumor volume below 3000 mm 3 after the second dosing. A dotted line in e indicates a 20% hCD45 reconstitution cutoff. g , Flow cytometric analysis for hCD45 + cells in peripheral blood collected from mouse 18025 and 18023 on day 20 and 24. See also .
Spf Nog Mice, supplied by Charles River Laboratories, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nog/pmc13135600-61-0-6?v=Charles+River+Laboratories
Average 86 stars, based on 1 article reviews
spf nog mice - by Bioz Stars, 2026-07
86/100 stars
  Buy from Supplier

Image Search Results


a , Timeline of the first animal study using NOG-hIL-15 (NOG15) mouse ( s.c. , i.p. and i.v. stand for subcutaneous, intraperitoneal and intravenous, respectively). b , Table showing specific amount of cells used for three dosings (see a ) in the humanized animals. c , Human leukocyte antigen (HLA) haplotype information for PBMC donor 416C (green) and 202C (magenta). Note that 416C is HLA-A2-positive. d - f , Data from the humanized mouse study showing tumor volume ( d ), the percent of human CD45 (hCD45) positive cells over total CD45 + cells (hCD45 + plus mCD45 + ) ( e ), and the amount of human hCD45 + /hCD3 - /hCD56 + NK cells ( f ) (see for flow cytometric gating strategy and percent/events conversion). A dotted line in d indicates that mice were supposed to be euthanized when the tumor volume was larger than 3000 mm 3 . Note that mouse 18019 was not euthanized on day 17 hoping the injected CAR-T cells might reduce tumor volume below 3000 mm 3 after the second dosing. A dotted line in e indicates a 20% hCD45 reconstitution cutoff. g , Flow cytometric analysis for hCD45 + cells in peripheral blood collected from mouse 18025 and 18023 on day 20 and 24. See also .

Journal: bioRxiv

Article Title: HLA-G engineering reprograms CAR-T cells with an immune privilege

doi: 10.64898/2026.05.10.723228

Figure Lengend Snippet: a , Timeline of the first animal study using NOG-hIL-15 (NOG15) mouse ( s.c. , i.p. and i.v. stand for subcutaneous, intraperitoneal and intravenous, respectively). b , Table showing specific amount of cells used for three dosings (see a ) in the humanized animals. c , Human leukocyte antigen (HLA) haplotype information for PBMC donor 416C (green) and 202C (magenta). Note that 416C is HLA-A2-positive. d - f , Data from the humanized mouse study showing tumor volume ( d ), the percent of human CD45 (hCD45) positive cells over total CD45 + cells (hCD45 + plus mCD45 + ) ( e ), and the amount of human hCD45 + /hCD3 - /hCD56 + NK cells ( f ) (see for flow cytometric gating strategy and percent/events conversion). A dotted line in d indicates that mice were supposed to be euthanized when the tumor volume was larger than 3000 mm 3 . Note that mouse 18019 was not euthanized on day 17 hoping the injected CAR-T cells might reduce tumor volume below 3000 mm 3 after the second dosing. A dotted line in e indicates a 20% hCD45 reconstitution cutoff. g , Flow cytometric analysis for hCD45 + cells in peripheral blood collected from mouse 18025 and 18023 on day 20 and 24. See also .

Article Snippet: 6-8 week old female NOD.Cg- Prkdc scid IL2rg tm1Sug Tg(CMV-IL2/IL15)1-1Jic/JicCrl mice, or NOG-hIL-15 (Charles River, Beijing) in short, were allowed to acclimate to the animal facility at the CRO for 5-7 days in a group-housing setting with 2–3 mice per cage in a reverse 12 hour light/dark cycle with ad libitum access to food and water.

Techniques: Injection